References

1. Sawaya ME. Alopecia—the search for novel agents continues. Exp Opin Ther Patents 1997; 7(8):859-872.

2. Abell E. Embryology and anatomy of the hair follicle. In: Olsen EA, ed. Disorders of Hair Growth Diagnosis and Treatment. New York: McGraw-Hill, 1994:119.

3. Montagna W. Baldness: a disease? J Am Med Wom Assoc 1973; 28:447-458.

4. Porter PS. The genetics of human hair growth. Birth Defects 1971; 7:69-85.

5. Bartosova L, Jorda V. Laboratory and experimental trichology. Curr Probl Dermatol 1984; 12:224-238.

6. Simpson NB, Barth JH. Hair patterns: Hirsuties and androgenetic alopecia. In: Dawber R, ed. Diseases of the Hair and Scalp, 3rd rev ed. Oxford: Blackwell Scientific, 1997:101-122.

7. Olsen EA. Androgenetic alopecia. In: Olsen EA, ed. Disorders of Hair Growth. Diagnosis and Treatment. New York: McGraw-Hill, 1994:257-283.

8. Sawaya ME, Price VH. Different levels of 5a-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109:296-300.

9. Sawaya ME. Androgen metabolism in androgenetic alopecia. In: Camacho F, Montagna W, eds. Trichology: Diseases of the Pilosebaceus Follicle. Madrid (Spain): Aula Medica Group, SA, 1997:317-323.

10. Kligman AM, Freeman B. History of baldness from magic to medicine. Clin Dermatol 1988; 6(4):83-88.

11. Norwood OT. Male pattern baldness: Classification and incidence. South Med J

7 T3

12. Ludwig E. Classification of the types of androgenetic alopecia (common baldness)

occurring in the female sex. Br J Dermatol 1977; 97: 247-254. g

13. Venning VA, Dawber RPR. Patterned androgenic alopecia in women. J Am Acad Ü Dermatol 1988; 18:1073-1077. Jf

14. World Health Organization. International statistical classification of diseases and ¿ related health problems, 10th rev ed. Geneva, 1992:616-617.

15. Montagna W. General review of the anatomy, growth, and development of hair in

<u man. In: Toda K, et al, eds. Biology and Disease of the Hair. Baltimore: University Park Press, 1976:xxi-xxxi.

16. Barman JM, Pecoraro V, Astore I. Biological basis of the inception and evolution of baldness. J Gerontol 1969; 24:163-168.

17. Maffei C, Fossati A, Rinaldi F, Riva E. Personality disorders and psychopathologic symptoms in patients with androgenetic alopecia. Arch Dermatol 1994; 130:868872.

18. Cash TF. The psychological effects of androgenetic alopecia in men. Am Acad Dermatol 1992; 26:926-931.

19. Cash TF, Price V, Savin R. The psychosocial effects of androgenetic alopecia among women: comparisons with balding men and female controls. J Am Acad Dermatol 1993; 29:568-575.

20. Buhl AE, Waldon DJ, Conrad SJ, Mulholland MJ, Shull KL, Kubicek MF, et al. Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol 1992; 98:315-319.

21. Trancik R, Rundergren J. Topical minoxidil 5 percent in the treatment of male androgenetic alopecia. J Invest Dermatol (in press).

22. Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41(5):717-721.

23. Ferry JJ, Forbes KK, VanderLugt JT, Szpunar GJ. Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution. Clin Pharmacol Ther 1990; 47:439-446.

24. Bazzano GS, Terezakis N, Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol 1986; 15:880-883, 890-893.

25. Comacho F. Medical treatment of androgenetic alopecia. In: Camacho F, Montagna W, eds. Trichology: Diseases of the Pilosebaceus Follicle. Madrid (Spain): Aula Medica Group, SA 1997:357-386.

26. Kaufman KD, Olsen EA, Whiting DA, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998; 39:578-589.

27. Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999; 40:930-937.

28. Propecia™ (finasteride) Tablets (1 mg) Package Insert, Merck & Co., Inc., December 1997.

29. Sawaya ME, Roth WI, Hevia O. Significance of RU58841 as a therapeutic agent effecting androgen receptor molecular interactions in human hair follicles. J Invest Dermatol 1995; 104:606.

30. Sawaya ME, Hordinsky MK. The antiandrogens, when and how they should be used.

Dermatol Clin 1993; 1:65-72. -d

31. Uno H, Ye F, Imamura K, Obana N, Bonfils A. Dose dependent and long-term § effects of RU58841 (androgen receptor blocker) on hair growth in the bald stump- 8 tailed macaque. J Invest Dermatol 1997; 108:680. ■§,

32. Uno H, Obana N, Cappas A, Rhodes L, Bonfils A. Follicular regrowth with 5a-

reductase inhibitor (finasteride) or androgen receptor blocker (RU58841) in the bald g scalp of the stumptailed macaque. J Invest Dermatol 1995; 104:658. g

33. Imamura K, Bonfils A, Diani A, Uno H. The effect of topical RU58841 (androgen 3

Hair Loss Prevention

Hair Loss Prevention

The best start to preventing hair loss is understanding the basics of hair what it is, how it grows, what system malfunctions can cause it to stop growing. And this ebook will cover the bases for you. Note that the contents here are not presented from a medical practitioner, and that any and all dietary and medical planning should be made under the guidance of your own medical and health practitioners. This content only presents overviews of hair loss prevention research for educational purposes and does not replace medical advice from a professional physician.

Get My Free Ebook


Post a comment